Major cancer doctor Richard Scolyer continues to be cancer-free a year after a significant seizure led to his diagnosis of brain cancer.
The Australian has undergone a planet- initial, exploratory treatment for glioblastoma, based on his own founding cancer research.
Most of his cancer’s type survive for less than a year because it is so intense.
However, the 57-year-old claimed on Tuesday that his most recent MRI scan revealed no tumor frequency.
” I could n’t be happier!!!!”! He updated his social media account.
Prof. Scolyer, along with his friend Georgina Long, and his partner Georgina Long, both received the award for their groundbreaking work on melanoma this year.
Co- directors of the Melanoma Institute Australia, over the past century their team’s studies on immunotherapy, which uses the body’s immune system to strike cancer cells, has significantly improved outcomes for superior melanoma patients worldwide. Half are now essentially cured, up from less than 10 %.
In order to cure Prof. Scolyer, Professor Long and a team of doctors are using that studies in the hope that Prof. Scolyer’s cancer can be treated as well.
Prof. Long and her team discovered that immunological works better when combined drugs are used and used before any tumor removal procedure. And therefore, Prof Scolyer next year became the first mind cancer individual to ever have combination, pre- surgery immunotherapy.
He is also the first to get administered a vaccination personalised to his tumour’s faculties, which boosts the cancer- monitoring capabilities of the drugs.
The pair’s recent findings have sparked a lot of excitement and optimism, with the hope that they may be making a breakthrough that could benefit the roughly 300,000 people who are diagnosed with brain cancer annually around the world.
The current protocol for treating glioblastomas was named in honor of Roger Stupp, who earlier this year informed the BBC Prof. Scolyer that it was too early to determine whether the treatment is effective.
He added that while Mr Scolyer’s earlier results were “encouraging” he wanted to see him reach 12 months, even 18, without recurrence before getting excited.
Although Prof. Scolyer and Prof. Long have previously stated that Prof. Scolyer’s chances of being treated are “minimum,” they hope the experimental treatment will help him live longer and lead to glioblastoma clinical trials.
